Actavis' Viberzi, Valeant's Xifaxan OK'd in IBS-D in US

The FDA on 27 May approved Actavis' and Patheon Pharmaceuticals' Viberzi (eluxadoline) and Valeant's and its subsidiary Salix's Xifaxan (rifaximin) to treat adults with irritable bowel syndrome with diarrhea (IBS-D).

The FDA on 27 May approved Actavis' and Patheon Pharmaceuticals' Viberzi (eluxadoline) and Valeant's and its subsidiary Salix's Xifaxan (rifaximin) to treat adults with irritable bowel syndrome with diarrhea (IBS-D).

As many as 35 million adult Americans may have IBS, with 40% of those experiencing the subtype with diarrhea symptoms,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category